Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Long Term Incentive Plan

5 Jun 2015 07:30

RNS Number : 3052P
Allied Minds PLC
05 June 2015
 



 

 

FOR RELEASE ON 05 JUNE 2015

 

Allied Minds plc (the "Company" or the "Group")

 

Long Term Incentive Plan

 

Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, announces that on 04 June 2015 it made conditional awards of 450,251 ordinary shares of one pence each ("Ordinary Shares") to certain directors, other persons discharging managerial responsibilities ("PDMRs") and certain other employees under its Long Term Incentive Plan (the "LTIP").

 

Conditional awards in the form of restricted share units have been made to the directors and PDMRs totalling 302,930 Ordinary Shares as follows:

 

Director/PDMR

Maximum number of Ordinary Shares conditionally awarded in respect of 2015 LTIP

Maximum number of conditionally awarded Ordinary Shares outstanding at the date of this announcement (including 2015 LTIP)

Chris Silva

126,630

1,524,971

Marc Eichenberger

65,357

904,362

Michael Turner

61,273

900,278

Omar Amirana

16,339

320,246

Svetoslav Milenkov

8,823

241,880

Peter Dolan (Non-Executive)

8,170

8,170

Richard Davis (Non-Executive)

5,446

5,446

Kevin Sharer (Non-Executive)

5,446

5,446

Jeffrey Rohr (Non-Executive)

5,446

5,446

 

The number of Ordinary Shares stated is the maximum number that could be issued to each director or PDMR upon full satisfaction of the performance conditions attaching to the awards. The awards granted to the non-executive directors are not subject to performance conditions, but instead vest in three equal tranches on the first, second and third anniversaries of grant, subject to the non-executive director continuing to provide services to the Group on the relevant vesting date.

 

In addition to the above, awards in the form of restricted share units over a total of 147,321 Ordinary Shares were made to certain other of the Group's employees pursuant to the 2015 LTIP.

 

The performance conditions attaching to the 2015 awards (other than the non-executive director awards) are based on the achievement of performance metrics measured as follows: 60% of each award will be subject to performance conditions based on the Company's total shareholder return (TSR) performance in respect of the period from 01 January 2015 through 31 December 2017; and 40% of each award will be subject to performance conditions based on a basket of shareholder value metrics (assessed on a scorecard basis over the three year period to 31 December 2017), including but not limited to: (i) the increase in quality of pipeline intellectual property reviewed; (ii) the increase in quality of the partnership pipeline; and (iii) subsidiary level performance (assessed by reference to such matters as external funding raised, corporate collaborations, product co-development and proof of principal commercial pilots and revenues), as further described in the Directors' Remuneration Report of the 2014 Annual Report and Accounts. The Group's Remuneration Policy and Annual Remuneration Report were recently approved by the Company's shareholders at its Annual General Meeting held on 28 May 2015.

 

The awards will vest, to the extent that the performance conditions have been satisfied, on the date following 31 December 2017 on which the extent to which the performance conditions have been satisfied is determined, and the Ordinary Shares will be issued as soon as practicable after such date.

 

As at the date of this announcement, a total of 5,048,700 Ordinary Shares have been conditionally awarded to directors, PDMRs and employees of the Company pursuant to the LTIP and remain subject to performance conditions (other than the non-executive director awards). The Company currently has 214,490,579 Ordinary Shares in issue.

 

About Allied Minds

 

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

 

For more information, please contact:

Allied Minds plc www.alliedminds.com

Peter Dolan, Non-Executive Chairman +1 617 419 1800

Chris Silva, Chief Executive Officer +1 617 419 1800

FTI Consulting

Ben Atwell, Matthew Cole +44 (0) 20 3727 1000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRGDLDGGBGUS
Date   Source Headline
31st Jan 20173:55 pmRNSTotal Voting Rights
30th Jan 201712:02 pmRNSPrice Monitoring Extension
3rd Jan 20172:48 pmRNSHolding(s) in Company
3rd Jan 20172:11 pmRNSTotal Voting Rights
13th Dec 20167:00 amRNSFormation of Signature Medical, Inc.
9th Dec 20165:04 pmRNSHolding(s) in Company
7th Dec 20164:34 pmRNSHolding(s) in Company
6th Dec 20165:05 pmRNSHolding(s) in Company
6th Dec 20165:04 pmRNSHolding(s) in Company
2nd Dec 20167:00 amRNSResults of equity placing
1st Dec 20164:50 pmRNSProposed Equity Placing
23rd Nov 20167:00 amRNSHawkEye 360 Raises $11m in Series A Financing
21st Nov 20167:00 amRNSFormation of Vatic Materials, Inc.
18th Nov 20163:15 pmRNSBlock Listing Six Monthly Return
11th Nov 20165:17 pmRNSHolding(s) in Company
24th Oct 20167:00 amRNSPrecision Biopsy Raises $5.0 Million
17th Oct 201612:07 pmRNSSecond Price Monitoring Extn
17th Oct 201612:02 pmRNSPrice Monitoring Extension
29th Sep 20167:00 amRNSAllied Minds & GE Ventures Form Strategic Alliance
8th Sep 201612:02 pmRNSPrice Monitoring Extension
31st Aug 20165:11 pmRNSTotal Voting Rights
25th Aug 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSAllied Minds Secures $20m Debt Facility from SVB
22nd Aug 20167:00 amRNSAllied Minds' Subsidiary ABLS II Raises $15m
1st Aug 20167:00 amRNSSciFluor Enters Clinical Trial Stage
29th Jul 201610:30 amRNSTotal Voting Rights
13th Jul 201610:02 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:00 amRNSDirector/PDMR Shareholding
7th Jul 20167:00 amRNSLong Term Incentive Plan - Listing Application
30th Jun 20167:00 amRNSTotal Voting Rights
22nd Jun 20164:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20164:35 pmRNSPrice Monitoring Extension
14th Jun 20162:38 pmRNSDirector/PDMR Shareholding
13th Jun 20165:18 pmRNSDirector/PDMR Shareholding
31st May 20164:44 pmRNSBlocklisting Six Monthly Return
26th May 20165:23 pmRNSResult of AGM
26th May 20167:00 amRNSAGM Statement
25th May 20167:00 amRNSABLS II Completes Drug Feasibility Programme
13th May 20167:00 amRNSDirector/PDMR Shareholding
10th May 20164:30 pmRNSLong Term Incentive Plan
28th Apr 201612:33 pmRNSHolding(s) in Company
26th Apr 20167:00 amRNSAllied Minds Raises $80m for ABLS Capital
25th Apr 20167:00 amRNSAnnual Financial Report
19th Apr 20167:00 amRNSAppointment of Joint Broker
16th Mar 20167:00 amRNSABLS agrees license with NYU
10th Feb 20164:40 pmRNSSecond Price Monitoring Extn
10th Feb 20164:36 pmRNSPrice Monitoring Extension
9th Feb 20164:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.